In recent years, chronic liver diseases have become a significant cause of death and disability [2], there is a trend towards an increase in the number of patients with chronic liver disease. It is widespread mainly among people of working age [3], which is explained by the living conditions of modern humans and the presence of a large number of chemical compounds in the environment. This leads to changes in metabolic processes in the liver and its toxic damage.

According to WHO data, over the past 20 years, there has been a trend towards an increase in the number of liver diseases leading to high mortality worldwide. Today, the number of patients with various hepatobiliary pathologies in the world exceeds 2 billion people. In the CIS countries alone, between 500,000 and 1 million people with various liver diseases are registered annually [4].

A sharp increase in the number of patients with chronic liver diseases was facilitated by an increase in the incidence of viral and toxic (alcoholic and drug) hepatitis, as well as a significant increase in the number of patients with obesity and diabetes mellitus.

The hepatoprotective properties of drugs improve metabolism, inhibit peroxidation, activate lipid metabolism, and protect mitochondrial and microsomal enzymes from damage to varying degrees [1].